Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta‐analysis of safety

Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta‐analysis of safety

Abstract Objective For patients with advanced or metastatic renal cell carcinoma (RCC), the dose of targeted agents was recommended in combination with immune checkpoint inhibitors. We performed a network meta‐analysis to describe a categorized safety ranking profile and assess the adaptability of t...

Full description

Bibliographic Details
Main Authors: Ruiyang Xie, Jie Wu, Bingqing Shang, Xingang Bi, Weixing Jiang, Chuanzhen Cao, Aiping Zhou, Hongzhe Shi, Jianzhong Shou
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
mTOR inhibitor
renal cell carcinoma
targeted agents
VEGF‐TKI
Online Access:https://doi.org/10.1002/cam4.5504

Similar Items

Similar Items